Company intelligence / Profile preview

WuXi Biologics

Ownership: Public · 2269.HK
Employees: ~12000
Development stage: Commercial

Overview

WuXi Biologics supports over 742 integrated client projects, including 16 in commercial manufacturing, spanning preclinical to commercial stages. The company enables partners to advance biologic drugs—including mAbs and next-generation modalities—through all phases of development. It has successfully completed large-scale manufacturing runs at its global facilities.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: AntibodyMonoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugateRecombinant proteinEnzyme replacement therapyGene therapyCell therapyVaccine
Industry: Drug Discovery Services

Partnerships

Virogen BiotechnologyCandid TherapeuticsMajor pharmaceutical companies globally

Financials

Market cap: $24.8B
Total revenue: $3.3B
Enterprise value: $23.2B

Beyond the preview

Go deeper on WuXi Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WuXi Biologics.